ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients

Diagnostic Cytopathology

Volumn 43, Issue 11, 2015, Pages 941-946

  Bozzetti, Cecilia ^a   Nizzoli, Rita ^a   Tiseo, Marcello ^a   Squadrilli, Anna ^a   Lagrasta, Costanza ^a   Buti, Sebastiano ^a   Gasparro, Donatello ^a   Zanoni, Daniele ^a   Majori, Maria ^a   De Filippo, Massimo ^a   Mazzoni, Francesca ^b   Maddau, Cristina ^c   Naldi, Nadia ^a   Sammarelli, Gabriella ^a   Frati, Caterina ^a   Pinto, Carmine ^a   Ardizzoni, Andrea ^d  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c Cancer Prevention and Research Institute   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ALK; cytology; FISH; non small cell lung cancer; ROS1

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CONTROLLED STUDY; CYTODIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; ROS1 GENE; SMEAR; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROCEDURES; VERY ELDERLY;

ANAPLASTIC LYMPHOMA KINASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CYTODIAGNOSIS; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84944162104     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.23318     Document Type: Article

References (30)

1. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
2. Shinmura K, Kageyama S, Tao H, et al., EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TGF-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 2008; 61: 163-169.
3. Koivunen JP, Mermel C, Zejnullahu K, et al., EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-4283.
4. Shaw AT, Yeap BY, Mino-Kenudson M, et al., Clinical features and outcome of patients with non-small-cell lung cancer who harbour EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
5. Sasaki T, Rodig SJ, Chirieac LR, et al., The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46: 1773-1780.
6. Shaw AT, Kim DW, Nakagawa K, et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
7. Tiseo M, Gelsomino F, Bartolotti M, et al., Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. Exp Rev Anticancer Ther 2011; 11: 1677-1687.
8. Solomon BJ, Mok T, Kim DW, et al., First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167-2177.
9. Bergethon K, Shaw AT, Ou SH, et al., ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-870.
10. Takeuchi K, Soda M, Togashi Y, et al., RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18: 378-381.
11. Go H, Kim DW, Kim D, et al., Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol 2013; 8: 1445-1450.
12. Shaw AT, Ou SH, Bang YJ, et al., Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371: 1963-1971.
13. Acquaviva J, Wong R, Charest A., The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009; 1795: 37-52.
14. Proietti A, Alì G, Pelliccioni S, et al., Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: Comparison with histological assessment. Cancer Cytopathol 2014; 122: 445-453.
15. Betz BL, Dixon CA, Weigelin HC, et al., The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma. Cancer Cytopathol 2013; 121: 489-499.
16. Neat MJ, Foot NJ, Hicks A, et al., ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer. Cytopathology 2013; 24: 356-364.
17. Cai G, Wong R, Chhieng D, et al., Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol 2013; 121: 500-507.
18. Savic S, Bode B, Diebold J, et al., Detection of ALK-positive non-small-cell lung cancers on cytological specimens: High accuracy of immunocytochemistry with the 5A4 clone. J Thorac Oncol 2013; 8: 1004-1011.
19. Sakairi Y, Sato K, Itoga S, et al., Transbronchial biopsy needle rinse solution used for comprehensive biomarker testing in patients with lung cancer. J Thorac Oncol 2014; 9: 26-32.
20. Lindeman NI, Cagle PT, Beasley MB, et al., Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013; 15: 415-453.
21. Nizzoli R, Tiseo M, Gelsomino F, et al., Accuracy of fine needle aspiration cytology in the pathological typing of Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2011; 6: 489-493.
22. Rivera MP, Mehta AC,; American College of Chest Physicians. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 131S-148S.
23. Bozzetti C, Naldi N, Nizzoli R, et al., Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer. Lung Cancer 2013; 80: 35-38.
24. Otani H, Toyooka S, Soh J, et al., Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients. J Thorac Oncol 2008; 3: 472-476.
25. Kanaji N, Bandoh S, Ishii T, et al., Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy. Lung Cancer 2012; 77: 293-298.
26. Bozzetti C, Tiseo M, Lagrasta C, et al., Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites. J Thorac Oncol 2008; 3: 18-22.
27. Salido M, Pijuan L, Martínez-Avilés L, et al., Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011; 6: 21-27.
28. D'Angelo SP, Pietanza MC, Johnson ML, et al., Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011; 29: 2066-2070.
29. Sholl LM, Sun H, Butaney M, et al., ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 2013; 37: 1441-1449.
30. Cha YJ, Lee JS, Kim HR, et al., Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS One 2014; 9: e103333.